Tarsier Pharma will fail to complete an IPO before September 2026, missing its scheduled July 9 pricing and leaving the planned $45 million raise unresolved. The Israel based biotech planned to offer 5 million shares at a proposed $8 to $10 range and to list on NYSE American under ticker TARX, and…